Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma. 2017

H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
Medizinische Klinik und Poliklinik II, Julius Maximilians Universität Würzburg, Würzburg, Germany.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy

Related Publications

H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
July 2022, The oncologist,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
October 2023, Current hematologic malignancy reports,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
May 2009, Nature reviews. Clinical oncology,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
October 2010, The Lancet. Oncology,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
January 2024, Bratislavske lekarske listy,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
September 2017, Drugs,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
January 2014, Chinese medical journal,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
November 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
March 2011, British journal of haematology,
H Einsele, and S Knop, and M Vogel, and J Müller, and M Kropff, and B Metzner, and C Langer, and H Sayer, and W Jung, and H A Dürk, and H Salwender, and H Wandt, and F Bassermann, and M Gramatzki, and W Rösler, and H-H Wolf, and W Brugger, and M Engelhardt, and T Fischer, and P Liebisch, and C Straka
October 2022, Journal of thrombosis and thrombolysis,
Copied contents to your clipboard!